$132.6 Billion Global Immuno-oncology Market to 2025 – Players Include Amgen, AstraZeneca and Novartis Among Others – ResearchAndMarkets.com | Financial Buzz

$132.6 Billion Global Immuno-oncology Market to 2025 – Players Include Amgen, AstraZeneca and Novartis Among Others – ResearchAndMarkets.com

The “I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market” report has been added to ResearchAndMarkets.com’s offering.

This study explores the global immuno-oncology (I-O) market’s evolution from 2020 to 2025. An extensive analysis is provided on the growth opportunities envisioned by the analyst to help stakeholders leverage their momentum and disrupt the market by offering best-in-class solutions.

The study considers oncology agents for which the immune system is the basis of their actions, including monoclonal antibodies, cell and gene therapies, bioengineered vaccines, recombinant products, small molecules, and oncolytic viruses. Classified into 5 major therapy types – immunomodulators, adoptive cell therapy, cancer vaccine, oncolytic virus, and antibody-based targeted therapies – the analysis provides revenue forecasts by the global market and product category. The agents are classified into various therapy types based on the mechanism of action (MOA). Concerning pipeline products, we have considered industry-sponsored products under development.

The oncology therapeutic segment is expected to witness minimal impact from the COVID-19 pandemic because of the criticality of treating cancer patients and the segment’s role as a major revenue-generator for pharmaceutical companies. The analyst have considered the impact of COVID-19 and two scenarios for the sales forecast: original scenario and COVID-19 impact scenario.

In the original scenario, the I-O market is expected to reach $132.66 billion by 2025 growing at a rate of 11.6% and witness minimal impact from the COVID-19 pandemic, with 2020 accounting for the majority of the decline. After 2022, the market will positively recuperate and experience a slight increase in revenue due to rebounding R&D budgets and accelerated developments of late-stage clinical candidates.

Companies Mentioned

  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eli Lilly
  • Johnson & Johnson
  • Merck & Co
  • Novartis
  • Pfizer
  • Roche

Major Themes Covered in This Study:

  • Strategic imperatives and key findings
  • Overview of I-O market, including the journey from bench to bedside, the value chain and stakeholder ecosystem, R&D expenditure, funding, and investment
  • Clinical trial overview for all therapies in consideration, with details for each I-O target and agent
  • Regulatory and reimbursement scenario, including risk-sharing models
  • Key marketed and pipeline products, market and technology dashboard
  • Extensive growth opportunity analysis with metrics, drivers, restraints, and competitive environment
  • Market revenue forecast and share analysis for each product segment
  • Calls to action aligned with the recommended growth opportunities
  • Key company profiles

Key Topics Covered:

1. Strategic Imperatives

2. Executive Summary

3. Market Overview-Immuno-oncology

  • Characteristics of Immuno-oncology Therapies-Journey from Bench to Bedside

4. Immuno-oncology Value Chain and R&D Expenditure-Immuno-oncology

  • Immuno-oncology Clinical Development Process and Approach
  • Immuno-oncology Value Chain and Stakeholder Ecosystem
  • Immuno-oncology from Early Stages to Product Launch
  • Immuno-oncology R&D Funding and Investment

5. Clinical Trial Overview-Immuno-oncology

  • Clinical Trials Snapshot for Immuno-oncology Therapies
  • Clinical Trials Snapshot for T-cell Targeting Immunomodulators
  • Clinical Trials Snapshot for Other Immunomodulators
  • Clinical Trials Snapshot for Adoptive Cell Therapies
  • Clinical Trials Snapshot for Targeted Cell Types
  • Clinical Trials Snapshot for Cancer Vaccines
  • Clinical Trials Snapshot for Oncolytic Viral Therapies
  • Clinical Trials Snapshot for Bispecific Antibodies (BsAbs)
  • Clinical Trials Snapshot for Immuno-oncology Agents
  • Clinical Trials Snapshot for Immuno-oncology Treatments

6. Regulatory and Reimbursement Scenario-Immuno-oncology

  • Regulatory Framework for Immuno-oncology Therapy Approval
  • Regulatory Approaches to Advance Immuno-oncology Therapies
  • Reimbursement Scenario across the Immuno-oncology Space
  • Risk Sharing Model for Immuno-oncology Therapies

7. Key Marketed and Pipeline Products Dashboard-Immuno-oncology

8. Growth Opportunity Analysis-Global Immuno-oncology Market

  • Global Immuno-oncology Market Scope of Analysis
  • Global Immuno-oncology Market Segmentation
  • Key Growth Metrics for Immuno-oncology Market
  • Growth Drivers for Immuno-oncology Market
  • Growth Restraints for Immuno-oncology Market
  • Forecast Assumptions-Global Immuno-oncology Market
  • Forecast Assumptions-Global Immuno-oncology Market (continued)
  • Revenue Forecast-Global Immuno-oncology Market
  • Revenue Forecast by Product-Global Immuno-oncology Market
  • Revenue Forecast Analysis-Global Immuno-oncology Market
  • Competitive Environment-Global Immuno-oncology Market
  • Revenue Share-Global Immuno-oncology Market
  • Revenue Share Analysis-Global Immuno-oncology Market

9. Growth Opportunity Analysis-Immunomodulators

  • Key Growth Metrics for Immunomodulators
  • Revenue Forecast-Immunomodulators
  • Forecast Analysis-Immunomodulators
  • Approved Immune Checkpoint Inhibitors as I-O Therapies
  • Approved Immunomodulators as I-O Therapies

10. Growth Opportunity Analysis-Adoptive Cell Therapy

  • Key Growth Metrics for Adoptive Cell Therapy
  • Revenue Forecast-Adoptive Cell Therapy
  • Forecast Analysis-Adoptive Cell Therapy
  • Autologous vs Allogeneic Adoptive Cell Therapy Challenges
  • Approved Adoptive Cell Therapies as I-O Therapies

11. Growth Opportunity Analysis-Antibody-based Targeted Therapies

  • Key Growth Metrics for Antibody-based Targeted Therapies
  • Revenue Forecast-Antibody-based Targeted Therapies
  • Forecast Analysis-Antibody-based Targeted Therapies
  • Approved Targeted Monoclonal Antibodies as I-O Therapies
  • Approved Antibody Drug Conjugates as I-O Therapies

12. Growth Opportunity Analysis-Cancer Vaccine and Oncolytic Virus

  • Key Growth Metrics for Cancer Vaccine and Oncolytic Virus
  • Revenue Forecast-Cancer Vaccine and Oncolytic Virus
  • Forecast Analysis-Cancer Vaccine and Oncolytic Virus
  • Approved Cancer Vaccines as I-O Therapies
  • Approved Oncolytic Virus as I-O Therapies

13. Growth Opportunity Universe-Immuno-oncology

14. Key Company Profiles – Immuno-oncology

15. Next Steps

For more information about this report visit https://www.researchandmarkets.com/r/ws05qn

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900